
Nektar Therapeutics (NKTR) Stock Forecast & Price Target
Nektar Therapeutics (NKTR) Analyst Ratings
Bulls say
Nektar Therapeutics has seen a significant increase in its outlook, with the price target raised to $165 per share due to positive clinical results from its immunotherapy pipeline, particularly the promising maintenance data from its rezpeg product in treating autoimmune diseases. The improved EASI-100 response rates and the increased probability of success for rezpeg in atopic dermatitis (AD) reflect stronger potential for market penetration, with estimates adjusted to a 60% probability and a 15% peak penetration rate. Furthermore, the advantages of dosing convenience and extended therapy benefits are likely to enhance patient adherence, strengthening Nektar's competitive position in the biologics landscape.
Bears say
Nektar Therapeutics faces significant risks related to the potential failure or delay in the development and commercialization of its key product candidates, particularly REZPEG, which are crucial for the company's future success. These developmental challenges could adversely affect revenue generation timelines and lead to material impacts on financial forecasts, thereby contributing to a negative outlook for the stock. Additionally, financial losses related to the revaluation of liabilities associated with future royalties and equity method investments further underscore the financial instability posed by the company's current operational challenges.
This aggregate rating is based on analysts' research of Nektar Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Nektar Therapeutics (NKTR) Analyst Forecast & Price Prediction
Start investing in Nektar Therapeutics (NKTR)
Order type
Buy in
Order amount
Est. shares
0 shares